MDS

Revlimid is showing promise for patients with low-risk MDS, according to the results of a recent study.

High cost does not always mean better chances of survival for elderly patients with MDS, according to a recent study.

An essay honoring Emily A. Knight, RN, OCN [Mayo Clinic Cancer Center in Scottsdale, Arizona.

Ruben A. Mesa addressed the current treatment landscape for PV last week at the 33rd Annual Chemotherapy Foundation Symposium, a meeting of over 1,000 physicians and other oncology professionals.

CURE interviewed Thomas Prebet to gain insight into the importance of supportive care in myelodysplastic syndrome.

Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses adverse events associated with treatment for myelodysplastic syndrome (MDS).

Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses the future of treating patients with myelodysplastic syndrome (MDS).

Treatment strategies for patients with MDS are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.

The Food and Drug Administration (FDA) has approved Jadenu (deferasirox) for the treatment of chronic iron overload, a condition that can affect patients with myelodysplastic syndromes (MDS), sickle cell disease and thalassemia.

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.

Robin Roberts, who was one of the most influential people in cancer last year, returns to "Good Morning America" today after recovering from MDS and a bone marrow transplantation.